ADC Therapeutics
ADCT | NYSE
$1.25
-$0.09 (-6.72%)
At close: Nov 16, 2026, 4:00 PM ET
$1.28
+$0.03 (+2.40%)
After-hours:
Nov 16, 2026, 5:35 PM ET
-6.72%
(1D)No price chart data available for 1D timeframe.
Rating
47.8
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #334/1021 (Top 33%)
Key Statistics
Market Data
Market Cap $194.26M
1D Range
1.25 1.35
52W Range
0.96 4.88
Valuation (TTM)
PE -2.40
PB -0.78
EV/EBITDA -5.92
Valuation (NTM)
Forward PE N/A
Forward PEG 0.05
Price Target $3.50
Cash Flow
FCF Yield -51.8%
SBC Adj. FCF Yield -60.6%
SBC Impact -17.1%
Margins
Gross Margin 88.5%
Operating Margin -98.9%
FCF Margin -119.6%
Growth (CAGR)
Revenue 3Y | 5Y -11.8% |
37.8%
Dil EPS 3Y | 5Y 64.3% |
23.1%
FCF 3Y | 5Y 14.3% |
8.2%
Returns
ROA -31.8%
ROE 37.0%
ROIC -44.6%
Financial Health
Net Debt
$230.39M
Current Ratio 3.05
Interest Coverage -1.58
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its ...
Sector Healthcare
Industry Biotechnology
Employees 191
IPO Date May 18, 2020
Website www.adctherapeutics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 9, 2026
EPS
-$0.16
Beat +24.71%
YoY:
+46.67% REV
$21.72M
Beat +16.13%
YoY:
+32.20%Next Earnings
Mar 9, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
3
Consensus
Hold
Price Target
$3.50
Upside
+180.00%
Buy (1)
Hold (2)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ADCT